Together, these companies European technology subject matter experts (SMEs) have been awarded €2.5m funding from the European commission under the H2020 Fast Track to Innovation (FTI) pilot. The funding will support development of a cell metabolism analysis platform that aims to become integral to in vitro cell biology and drug development.
For Axiogenesis, the advancement of this cell metabolism platform comprises an important strategic fit given that it nicely complements the currently offered solutions which are mainly functional assays and services. Based in Irelan, Luxcel Biosciences specializes in cost effective and easy to use fluorescence-based in vitro cell test kits, targeting cell metabolism, bioenergetics and drug toxicity applications. BMG LABTECH offers high-quality and reliable microplate readers for life sciences applications and high-throughput screening.
Founded in 2001 and headquartered in Cologne, Germany, Axiogenesis initially focused on generating mouse embryonic stem cell derived cells and assays. After Yamanaka’s groundbreaking iPSC technology became available, Axiogenesis was the first European company to license and adopt Yamanaka’s iPSC technology in 2010.
According to Felix von Haniel, Commercial Director at Axiogenesis, “We are very excited to be part of this consortium. It greatly adds to our current portfolio, and broadens our application range in that it focuses not only on the safety / toxicity market, but in particular on drug discovery in the metabolic area. Also, the availability of ready-to-use kits makes iPSC-derived cells more accessible to a broader range of users, and is aligned with Axiogenesis’ philosophy to provide easy-to-implement iPSC-derived cells along with validated, physiologically relevant assays.”
Up Next: Top 10 Differentiators for Axiogenesis within the Global iPSC Marketplace